Boryung's multiple myeloma drug Pomalikin Cap may soon be released in Korea’s market.

The drug is the first generic version of Pomalyst Cap (pomalidomide, BMS). The risk-sharing agreement (RSA) applied to the original drug, Pomalyst Cap, ended this month, and the insurance price cap of the drug had been adjusted following the reimbursement application of its generic drug, Pomalikin Cap.

According to industry sources, four dosage forms (1mg, 2mg, 3mg, and 4mg) of Pomalikin Cap, which were approved in August last year, are expected to be listed for reimbursement and be released to the market soon.

The insurance price ceiling of the original drug has already been adjusted u